Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping
Rubí Hernández-López, Attila T Lorincz, Leticia Torres-Ibarra, Caroline Reuter, Dorota Scibior-Bentkowska, Rhian Warman, Belinda Nedjai, Indira Mendiola-Pastrana, Leith León-Maldonado, Berenice Rivera-Paredez, Paula Ramírez-Palacios, Eduardo Lazcano-Ponce, Jack Cuzick, Jorge Salmerón, FRIDA Study Group, Attila Lorincz, Cosette Wheeler, Patti Gravitt, Eduardo Lazcano, Leticia Torres, Leith León, Paula Ramírez, Berenice Rivera, Eduardo L Franco, Jack Cuzick, Pablo Méndez, Jorge Salmerón, Mauricio Hernández, Anna Barbara Moscicki, Yvonne Flores, Enrique Carmona, Kathleen M Schmeler, David Bishai, Pilar Hernández, Rubi Hernández, Indira Mendiola, Rubí Hernández-López, Attila T Lorincz, Leticia Torres-Ibarra, Caroline Reuter, Dorota Scibior-Bentkowska, Rhian Warman, Belinda Nedjai, Indira Mendiola-Pastrana, Leith León-Maldonado, Berenice Rivera-Paredez, Paula Ramírez-Palacios, Eduardo Lazcano-Ponce, Jack Cuzick, Jorge Salmerón, FRIDA Study Group, Attila Lorincz, Cosette Wheeler, Patti Gravitt, Eduardo Lazcano, Leticia Torres, Leith León, Paula Ramírez, Berenice Rivera, Eduardo L Franco, Jack Cuzick, Pablo Méndez, Jorge Salmerón, Mauricio Hernández, Anna Barbara Moscicki, Yvonne Flores, Enrique Carmona, Kathleen M Schmeler, David Bishai, Pilar Hernández, Rubi Hernández, Indira Mendiola
Abstract
Background: Vigilant management of women with high-risk human papillomavirus (hrHPV) is necessary in cancer screening programs. To this end, we evaluated the performance of S5 (targeting DNA methylation in HPV16, HPV18, HPV31, HPV33, and human gene EPB41L3) to predict cervical intraepithelial neoplasia grade 2 or higher (CIN2+) in a sample of hrHPV-infected women referred to colposcopy in the FRIDA Study, a large screening trial in Mexico. A nested case-control sample with women referred to colposcopy either by atypical squamous cells of undetermined significance or higher (ASCUS+) in cytology and/or positive for HPV types 16 or 18 was tested by S5. Seventy-nine cases of CIN2+ were age-matched to 237 controls without a diagnosis of CIN2+ (<CIN2). DNA from exfoliated cervical cells was bisulfite converted and PCR amplified for S5 targets, and methylation was quantified at specific cytosines by pyrosequencing.
Results: The S5 classifier separated women with CIN2+ from <CIN2 with a highly significant area under the curve (AUC) of 0.75 (95% CI 0.69-0.82), while AUC for CIN3+ was 0.81 (95% CI 0.74-0.89). To optimize sensitivity and specificity for Mexico, an alternative S5 cutoff of 3.7 was implemented to account for overall higher methylation seen in our already triaged women. All three invasive cancers were detected by methylation or HPV16/18 but none by cytology. Sensitivity of S5 for CIN2+ was 62% (95% CI 50.4-72.7%), specificity was 73% (95% CI 66.9-78.5%), and adjusted PPV was 15.1% (95% CI 12.0-18.3%). In contrast, the crude sensitivity of HPV16/18 detection and cytology were 63.3% (95% CI 51.7-73.9%) and 57.0% (95% CI 45.3-68.1%) respectively; specificity was 29.1% (95% CI 23.4-35.3%) and 62.4% (95% CI 55.9-68.6%) respectively, while adjusted PPV was 6.4% (95% CI 4.9-8.1%) and 10.5% (95% CI 8.0-13.1%), respectively. Methylation testing could reduce colposcopy referrals by 30 to 50% with virtually no loss of sensitivity for CIN2+ and CIN3+.
Conclusions: S5 testing on hrHPV-positive women significantly increased diagnostic information compared to triage by HPV16/18 plus cytology and appears to have clinical utility as an additional test to substantially lessen burdens on colposcopy.
Trial registration: The FRIDA Study is registered in ClinicalTrials.gov , number NCT02510027.
Keywords: Cervical cancer; Cervical intraepithelial neoplasia; DNA methylation; EPB41L3; Human papillomavirus; S5 classifier; Triage.
Conflict of interest statement
JS and ELP have received funding for research projects from Qiagen, Roche, Beckton Dickinson, Gen-Probe, DICIPA, and Arbor Vita. The other authors declare no competing interests.
Figures
References
- IARC. GLOBOCAN2018 [Internet]. [cited 2018 Dec 22]. Available from:
- Popat K, McQueen K, Feeley TW. The global burden of cancer. Best practice & research Clinical anaesthesiology. 2013;27(4).
- Schiffman Mark, Castle Philip E, Jeronimo Jose, Rodriguez Ana C, Wacholder Sholom. Human papillomavirus and cervical cancer. The Lancet. 2007;370(9590):890–907. doi: 10.1016/S0140-6736(07)61416-0.
- Lazcano-Ponce Eduardo, Lörincz Attila T., Salmerón Jorge, Fernández Irma, Cruz Aurelio, Hernández Pilar, Mejia Ivonne, Hernández-Ávila Mauricio. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes & Control. 2010;21(10):1693–1700. doi: 10.1007/s10552-010-9598-2.
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Jounal Pathology. 1999;189(1).
- Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Cmaj. 2001;164:7.
- Muñoz Nubia, Bosch F. Xavier, de Sanjosé Silvia, Herrero Rolando, Castellsagué Xavier, Shah Keerti V., Snijders Peter J.F., Meijer Chris J.L.M. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. New England Journal of Medicine. 2003;348(6):518–527. doi: 10.1056/NEJMoa021641.
- Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster WKR. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;9:3.
- Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9:9.
- Campos Nicole G., Maza Mauricio, Alfaro Karla, Gage Julia C., Castle Philip E., Felix Juan C., Cremer Miriam L., Kim Jane J. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. International Journal of Cancer. 2015;137(4):893–902. doi: 10.1002/ijc.29438.
- Ronco Guglielmo, Dillner Joakim, Elfström K Miriam, Tunesi Sara, Snijders Peter J F, Arbyn Marc, Kitchener Henry, Segnan Nereo, Gilham Clare, Giorgi-Rossi Paolo, Berkhof Johannes, Peto Julian, Meijer Chris J L M. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916):524–532. doi: 10.1016/S0140-6736(13)62218-7.
- Castle P. E., Schiffman M., Wheeler C. M., Wentzensen N., Gravitt P. E. Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Precancer. American Journal of Epidemiology. 2009;171(2):155–163. doi: 10.1093/aje/kwp390.
- Schiffman Mark, Wheeler Cosette M., Castle Philip E. Human Papillomavirus DNA Remains Detectable Longer than Related Cervical Cytologic Abnormalities. The Journal of Infectious Diseases. 2002;186(8):1169–1172. doi: 10.1086/343816.
- Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53:1. doi: 10.1016/j.ypmed.2011.08.017.
- Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl. 3):78–89. doi: 10.1016/j.vaccine.2006.05.117.
- Rao Arundhati, Sandri Maria Teresa, Sideri Mario, Young Stephen, Sharma Abha, Behrens Catherine. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. Journal of Clinical Virology. 2013;58(1):161–167. doi: 10.1016/j.jcv.2013.06.041.
- Fields RP. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. New England Journal Medicine. 2008;358(6).
- Flores Yvonne N., Bishai David M., Lőrincz Attila, Shah Keerti V., Lazcano-Ponce Eduardo, Hernández Mauricio, Granados-García Víctor, Pérez Ruth, Salmerón Jorge. HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico. Cancer Causes & Control. 2010;22(2):261–272. doi: 10.1007/s10552-010-9694-3.
- Mayrand Marie-Hélène, Duarte-Franco Eliane, Rodrigues Isabel, Walter Stephen D., Hanley James, Ferenczy Alex, Ratnam Sam, Coutlée François, Franco Eduardo L. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine. 2007;357(16):1579–1588. doi: 10.1056/NEJMoa071430.
- Huh Warner K., Williams Erin, Huang Joice, Bramley Tommy, Poulios Nick. Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening. Applied Health Economics and Health Policy. 2014;13(1):95–107. doi: 10.1007/s40258-014-0135-4.
- Lai Hung-Cheng, Lin Ya-Wen, Huang Tim H.M., Yan Pearlly, Huang Rui-Lan, Wang Hui-Chen, Liu Joseph, Chan Michael W.Y., Chu Tang-Yuan, Sun Chien-An, Chang Cheng-Chang, Yu Mu-Hsien. Identification of novel DNA methylation markers in cervical cancer. International Journal of Cancer. 2008;123(1):161–167. doi: 10.1002/ijc.23519.
- Lorincz Attila T, Brentnall Adam R, Vasiljević Nataša, Scibior-Bentkowska Dorota, Castanon Alejandra, Fiander Alison, Powell Ned, Tristram Amanda, Cuzick Jack, Sasieni Peter. HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. International Journal of Cancer. 2013;133(3):637–644. doi: 10.1002/ijc.28050.
- Mirabello Lisa, Schiffman Mark, Ghosh Arpita, Rodriguez Ana C., Vasiljevic Natasa, Wentzensen Nicolas, Herrero Rolando, Hildesheim Allan, Wacholder Sholom, Scibior-Bentkowska Dorota, Burk Robert D., Lorincz Attila T. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. International Journal of Cancer. 2012;132(6):1412–1422. doi: 10.1002/ijc.27750.
- Lorincz Attila T. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Review of Molecular Diagnostics. 2014;14(3):293–305. doi: 10.1586/14737159.2014.897610.
- Denis Hélène, Ndlovu 'Matladi N, Fuks François. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO reports. 2011;12(7):647–656. doi: 10.1038/embor.2011.110.
- Louvanto K, Franco EL, Ramanakumar AV, Vasiljevi N, Scibior-Bentkowska D, Koushik A, et al. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. International Journal of Cancer. 2015;136:6. doi: 10.1002/ijc.29196.
- Vasiljević Nataša, Scibior-Bentkowska Dorota, Brentnall Adam, Cuzick Jack, Lorincz Attila. A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. Journal of Clinical Virology. 2014;59(3):161–166. doi: 10.1016/j.jcv.2013.12.014.
- Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, et al. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. International Journal of Cancer. 2018.
- Nedjai Belinda, Reuter Caroline, Ahmad Amar, Banwait Rawinder, Warman Rhian, Carton James, Boer Sabrina, Cuzick Jack, Lorincz Attila T. Molecular progression to cervical precancer, epigenetic switch or sequential model? International Journal of Cancer. 2018;143(7):1720–1730. doi: 10.1002/ijc.31549.
- Brentnall Adam R., Vasiljević Nataša, Scibior-Bentkowska Dorota, Cadman Louise, Austin Janet, Szarewski Anne, Cuzick Jack, Lorincz Attila T. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. International Journal of Cancer. 2014;135(6):1425–1432. doi: 10.1002/ijc.28790.
- Brentnall Adam R., Vasiljevic Natasa, Scibior-Bentkowska Dorota, Cadman Louise, Austin Janet, Cuzick Jack, Lorincz Attila T. HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier. Cancer Biomarkers. 2015;15(5):669–675. doi: 10.3233/CBM-150507.
- Lorincz Attila T., Brentnall Adam R., Scibior-Bentkowska Dorota, Reuter Caroline, Banwait Rawinder, Cadman Louise, Austin Janet, Cuzick Jack, Vasiljević Natasa. Validation of a DNA methylation HPV triage classifier in a screening sample. International Journal of Cancer. 2016;138(11):2745–2751. doi: 10.1002/ijc.30008.
- Van BR, Van Der MJ, Snijders PJF, Rodriquez-manfredi A, Harmsel B, Van Den MHAM, et al. CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies. International Journal of Cancer. 2016;138.
- How Kit Alexandre, Nielsen Helene Myrtue, Tost Jörg. DNA methylation based biomarkers: Practical considerations and applications. Biochimie. 2012;94(11):2314–2337. doi: 10.1016/j.biochi.2012.07.014.
- Clarke MA, Luhn P, Gage JC, Bodelon C, Dunn ST, Walker J, et al. Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. International Journal of Cancer. 2017;710.
- Clarke Megan A., Gradissimo Ana, Schiffman Mark, Lam Jessica, Sollecito Christopher C., Fetterman Barbara, Lorey Thomas, Poitras Nancy, Raine-Bennett Tina R., Castle Philip E., Wentzensen Nicolas, Burk Robert D. Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women. Clinical Cancer Research. 2018;24(9):2194–2202. doi: 10.1158/1078-0432.CCR-17-3251.
- Schmitz M, Eichelkraut K, Schmidt D, Zeiser I, Hilal Z, Tettenborn Z, et al. Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages. BMC Cancer. 2018;18(1).
- Floore A, Hesselink A, Oštrbenk A, Alcaniz E, Rothe B, Pedersen H, et al. Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: results from an international study. 2019;33(e22854).
- Schmitz M, Wunsch K, Hoyer H, Scheungraber C, Runnebaum IB, Hansel A, et al. Performance of a methylation specific real-time PCR assay as a triage test for HPV-positive women. Clinical epigenetics. 2017;9.
- Vasiljević Nataša, Scibior-Bentkowska Dorota, Brentnall Adam R., Cuzick Jack, Lorincz Attila T. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecologic Oncology. 2014;132(3):709–714. doi: 10.1016/j.ygyno.2014.02.001.
- Lorincz AT. Virtues and weaknesses of DNA methylation as a test for cervical cancer. Acta Cytologica. 2016.
- Lazcano-Ponce E, Lorincz A, Torres L, Salmerón J, Cruz A, Rojas R. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. International Journal of Cancer. 2014;116.
- Beal Christyn M, Salmerón Jorge, Flores Yvonne N, Torres Leticia, Granados-García Víctor, Dugan Ellen, Lazcano-Ponce Eduardo. Cost analysis of different cervical cancer screening strategies in Mexico. Salud Pública de México. 2014;56(5):492. doi: 10.21149/spm.v56i5.7374.
- de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The lancet oncology [Internet]. 2010 Nov [cited 2014 Jul 23];11(11). Available from:
- Wentzensen Nicolas, Sun Chang, Ghosh Arpita, Kinney Walter, Mirabello Lisa, Wacholder Sholom, Shaber Ruth, LaMere Brandon, Clarke Megan, Lorincz Attila T., Castle Philip E., Schiffman Mark, Burk Robert D. Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3. JNCI: Journal of the National Cancer Institute. 2012;104(22):1738–1749. doi: 10.1093/jnci/djs425.
- Snijders P, Cubie H, Lorincz A, Ogilvie G, Franceschi S, Arbyn M, et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. International Journal of Cancer. 2018;143(4).
- Torres-Ibarra Leticia, Lazcano-Ponce Eduardo, Franco Eduardo L, Cuzick Jack, Hernández-Ávila Mauricio, Lorincz Attila, Rivera Berenice, Ramírez Paula, Mendiola-Pastrana Indira, Rudolph Samantha E, León-Maldonad Leith, Hernández Rubí, Barrios Elizabeth, Gravitt Patti, Moscicki Anna Barbara, Schmeler Kathleen M, Flores Yvonne N, Méndez-Hernández Pablo, Salmerón Jorge. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Pública de México. 2016;58(2):197–210. doi: 10.21149/spm.v58i2.7789.
Source: PubMed